Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management

Guoying Ni; Tianfang Wang; Lin Yang; Yuejian Wang; Xiao Song Liu; Ming Q Wei

doi:10.1080/21645515.2015.1089008

Back

Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management

Journal article

Peer reviewed

Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management

Guoying Ni, Tianfang Wang, Lin Yang, Yuejian Wang, Xiao Song Liu and Ming Q Wei

Human Vaccines & Immunotherapeutics, Vol.12(3), pp.599-606

2016

DOI: https://doi.org/10.1080/21645515.2015.1089008

Files and links (1)

url

https://doi.org/10.1080/21645515.2015.1089008View

Published Version

Abstract

anaerobic bacterial oncolysis

interleukin 10 (IL-10)

therapeutic vaccine

Late stage solid tumors cause significant cancer mortality rates worldwide and effective therapy remains a big challenge. Cancer therapeutic vaccines elicit tumor specific T cells that kill tumor cells yet often fail to result in tumor destruction because of the limited T cell response and the local immune-suppressive environment. Blocking interleukin 10 (IL-10) signaling at the time of therapeutic vaccination elicits much stronger T cell responses than vaccination without IL-10 blocking. Anaerobic oncolytic bacteria target hypoxic regions of the late stage tumor tissues which not only stops tumor growth but also provides a pro-inflammatory environment that may increase the effectiveness of a therapeutic vaccine by recruiting more effector T cells to tumor site. In this review, we argue that combining both bacterial and vaccine therapies may improve the efficiency of late stage cancer management.

Details

Title: Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management
Authors: Guoying Ni (Author) - Griffith University
Tianfang Wang (Author) - University of the Sunshine Coast - Faculty of Science, Health, Education and Engineering
Lin Yang (Author) - Tangshan Gongren Hospital, China
Yuejian Wang (Author) - Foshan First People's Hospital, China
Xiao Song Liu (Author) - University of the Sunshine Coast - Faculty of Science, Health, Education and Engineering
Ming Q Wei (Author) - Griffith University
Publication details: Human Vaccines & Immunotherapeutics, Vol.12(3), pp.599-606
Publisher: Taylor & Francis Inc.
Date published: 2016
DOI: 10.1080/21645515.2015.1089008
ISSN: 2164-5515
Organisation Unit: School of Science and Engineering - Legacy; University of the Sunshine Coast, Queensland; GeneCology Research Centre - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
Language: English
Record Identifier: 99449696302621
Output Type: Journal article

Metrics

6 File views/ downloads

728 Record Views

3 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Biotechnology & Applied Microbiology; Immunology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites